Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE)

British Journal of Haematology

Volumn 158, Issue 5, 2012, Pages 649-656

  Gorde Grosjean, Stéphanie ^a   Oberlin, Odile ^b   Leblanc, Thierry ^c   Pacquement, Hélène ^d   Donadieu, Jean ^e   Lambilliotte, Anne ^f   Schell, Mathias ^g   Dommange, Florence ^g   Munzer, Martine ^a   Paillard, Catherine ^h   Schmitt, Claudine ⁱ   Lutz, Patrick ^j   Edan, Christine ^k   Ansoborlo, Sophie ^l   Stephan, Jean Louis ^m   Michel, Gérard ⁿ   Thomas, Caroline ^o   Perel, Yves ^p   Robert, Alain ^q   Landman Parker, Judith ^c,r  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSTITUT CURIE   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g IHOP   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l CHG Saintes   (France)

^m UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁿ TIMONE HOSPITAL   (France)

^o NANTES UNIVERSITY HOSPITAL   (France)

^p BORDEAUX UNIVERSITY HOSPITAL   (France)

^q CHU PURPAN   (France)

^r SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

Adolescents; Autologous transplantation; Children; Hodgkin lymphoma; Relapse

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOGUAZONE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLASSICAL HODGKIN LYMPHOMA; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; REFRACTORY PERIOD; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84865144242     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09199.x     Document Type: Article

References (37)

1. Baker, K.S., Gordon, B.G., Gross, T.G., Abromowitch, M.A., Lyden, E.R., Lynch, J.C., Vose, J.M., Armitage, J.O., Coccia, P.F. & Bierman, P.J. (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. Journal of Clinical Oncology, 17, 825-831.
2. Behrendt, H., Van Bunningen, B.N. & Van Leeuwen, E.F. (1987) Treatment of Hodgkin's disease in children with or without radiotherapy. Cancer, 59, 1870-1873.
3. Brice, P. (2008) Managing relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 141, 3-13.
4. Byrne, B.J. & Gockerman, J.P. (2007) Salvage therapy in Hodgkin's lymphoma. Oncologist, 12, 156-167.
5. Cashen, A.F. & Bartlett, N.L. (2007) Therapy of relapsed Hodgkin lymphoma. Blood Reviews, 21, 233-243.
6. Chopra, R., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G. & Goldstone, A.H. (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood, 81, 1137-1145.
7. Claviez, A., Canals, C., Dierickx, D., Stein, J., Badell, I., Pession, A., Mackinnon, S., Slavin, S., Dalle, J.H., Chacon, M.J., Sarhan, M., Wynn, R.F., Suttorp, M., Dini, G., Sureda, A. & Schmitz, N. (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood, 114, 2060-2067.
8. Ferme, C., Bastion, Y., Lepage, E., Berger, F., Brice, P., Morel, P., Gabarre, J., Nedellec, G., Reman, O., Cheron, N., Oberlin, O.& Coiffier, B. (1995) The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Annals of Oncology, 6, 543-549.
9. Harris, R.E., Termuhlen, A.M., Smith, L.M., Lynch, J., Henry, M.M., Perkins, S.L., Gross, T.G., Warkentin, P., Vlachos, A., Harrison, L. & Cairo, M.S. (2011) Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant, 17, 249-258.
10. Horning, S.J., Chao, N.J., Negrin, R.S., Hoppe, R.T., Long, G.D., Hu, W.W., Wong, R.M., Brown, B.W. & Blume, K.G. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood, 89, 801-813.
11. Hudson, M.M., Greenwald, C., Thompson, E., Wilimas, J., Marina, N., Fairclough, D., Kauffman, W., Bozeman, P., Mackert, P.W. & Abromowitch, M. (1993) Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. Journal of Clinical Oncology, 11, 100-108.
12. Hudson, M.M., Krasin, M., Link, M.P., Donaldson, S.S., Billups, C., Merchant, T.E., Kun, L., Billet, A.L., Kaste, S., Tarbell, N.J., Howard, S., Friedmann, A.M., Hurwitz, C.A., Young, J.A., Marcus, K.C., Rai, S., Cowan, T. & Weinstein, H.J. (2004) Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. Journal of Clinical Oncology, 22, 4541-4550.
13. Josting, A., Engert, A., Diehl, V. & Canellos, G.P. (2002) Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Annals of Oncology, 13(Suppl 1), 112-116.
14. Josting, A., Nogova, L., Franklin, J., Glossmann, J.P., Eich, H.T., Sieber, M., Schober, T., Boettcher, H.D., Schulz, U., Muller, R.P., Diehl, V. & Engert, A. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 23, 1522-1529.
15. Landman-Parker, J., Pacquement, H., Leblanc, T., Habrand, J.L., Terrier-Lacombe, M.J., Bertrand, Y., Perel, Y., Robert, A., Coze, C., Thuret, I., Donadieu, J., Schaison, G., Leverger, G., Lemerle, J. & Oberlin, O. (2000) Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. Journal of Clinical Oncology, 18, 1500-1507.
16. Lieskovsky, Y.E., Donaldson, S.S., Torres, M.A., Wong, R.M., Amylon, M.D., Link, M.P. & Agarwal, R. (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. Journal of Clinical Oncology, 22, 4532-4540.
17. Lohri, A., Barnett, M., Fairey, R.N., O'Reilly, S.E., Phillips, G.L., Reece, D., Voss, N. & Connors, J.M. (1991) Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood, 77, 2292-2298.
18. Metzger, M.L., Hudson, M.M., Krasin, M.J., Wu, J., Kaste, S.C., Kun, L.E., Sandlund, J.T. & Howard, S.C. (2010) Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer, 116, 4376-4384.
19. Milpied, N., Fielding, A.K., Pearce, R.M., Ernst, P. & Goldstone, A.H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. Journal of Clinical Oncology, 14, 1291-1296.
20. Morschhauser, F., Brice, P., Ferme, C., Divine, M., Salles, G., Bouabdallah, R., Sebban, C., Voillat, L., Casasnovas, O., Stamatoullas, A., Bouabdallah, K., Andre, M., Jais, J.P., Cazals-Hatem, D. & Gisselbrecht, C. (2008) Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Journal of Clinical Oncology, 26, 5980-5987.
21. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzalez, M., Zelenetz, A.D. & Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology, 124, 645-652.
22. Oberlin, O., Leverger, G., Pacquement, H., Raquin, M.A., Chompret, A., Habrand, J.L., Terrier-Lacombe, M.J., Bey, P., Bertrand, Y. & Rubie, H. (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. Journal of Clinical Oncology, 10, 1602-1608.
23. Peggs, K.S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A., Thomson, K.J., Morris, E.C., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, 1934-1941.
24. Robinson, S.P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., Iriondo, A., Cook, G., Pettitt, A., Socie, G., Bonifazi, F., Bosi, A., Michallet, M., Liakopoulou, E., Maertens, J., Passweg, J., Clarke, F., Martino, R. & Schmitz, N. (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica, 94, 230-238.
25. Schellong, G., Potter, R., Bramswig, J., Wagner, W., Prott, F.J., Dorffel, W., Korholz, D., Mann, G., Rath, B., Reiter, A., Weissbach, G., Riepenhausen, M., Thiemann, M. & Schwarze, E.W. (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. Journal of Clinical Oncology, 17, 3736-3744.
26. Schellong, G., Dorffel, W., Claviez, A., Korholz, D., Mann, G., Scheel-Walter, H.G., Bokkerink, J.P., Riepenhausen, M., Luders, H., Potter, R. & Ruhl, U. (2005) Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. Journal of Clinical Oncology, 23, 6181-6189.
27. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
28. Shafer, J.A., Heslop, H.E., Brenner, M.K., Carrum, G., Wu, M.F., Liu, H., Ahmed, N., Gottschalk, S., Kamble, R., Leung, K.S., Myers, G.D., Bollard, C.M. & Krance, R.A. (2011) Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leukaemia & Lymphoma, 51, 664-670.
29. Sirohi, B., Cunningham, D., Powles, R., Murphy, F., Arkenau, T., Norman, A., Oates, J., Wotherspoon, A. & Horwich, A. (2008) Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology, 19, 1312-1319.
30. Stoneham, S., Ashley, S., Pinkerton, C.R., Wallace, W.H. & Shankar, A.G. (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. Journal of Pediatric Hematology/oncology, 26, 740-745.
31. Sureda, A. & Schmitz, N. (2002) Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. Annals of Oncology, 13(Suppl 1), 128-132.
32. Sureda, A., Robinson, S., Canals, C., Carella, A.M., Boogaerts, M.A., Caballero, D., Hunter, A.E., Kanz, L., Slavin, S., Cornelissen, J.J., Gramatzki, M., Niederwieser, D., Russell, N.H. & Schmitz, N. (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 26, 455-462.
33. Verdeguer, A., Pardo, N., Madero, L., Martinez, A., Bureo, E., Fernandez, J.M., Munoz, A., Olive, T., Fernandez-Delgado, R., Cubells, J., Diaz, M.A. & Sastre, A. (2000) Autologous stem cell transplantation for advanced Hodgkin's disease in children.Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplantation, 25, 31-34.
34. Williams, C.D., Goldstone, A.H., Pearce, R., Green, S., Armitage, J.O., Carella, A. & Meloni, G. (1993) Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. Journal of Clinical Oncology, 11, 2243-2249.
35. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 363, 1812-1821.
36. Younes, A., Oki, Y., Bociek, R.G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., Li, Z., Drouin, M., Patterson, T., Ward, M.R., Paulus, J.K., Ji, Y., Medeiros, L.J. & Martell, R.E. (2011) Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol, 12, 1222-1228.
37. Yuen, A.R., Rosenberg, S.A., Hoppe, R.T., Halpern, J.D. & Horning, S.J. (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89, 814-822.